ClinicalTrials.Veeva

Menu
P

Presbyterian Kaseman Hospital | Oncology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cisplatin
Paclitaxel
Trastuzumab
Atezolizumab
Lenalidomide
Nivolumab
Exemestane
Gemcitabine Hydrochloride
Bevacizumab
Pembrolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 82 total trials
Locations recently updated

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor D...

Enrolling
Stage III Colon Cancer
Drug: mFOLFOX6 3-6 month
Device: Signatera test

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting
Colorectal Neoplasms
Drug: Eflornithine placebo & sulindac placebo
Drug: Eflornithine plus sulindac

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in pa...

Enrolling
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Biological: Trastuzumab Emtansine
Other: Quality-of-Life Assessment

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harb...

Enrolling
Multiple Myeloma
Advanced Solid Tumors
Drug: Trastuzumab and Pertuzumab
Drug: Palbociclib

Trial sponsors

National Cancer Institute (NCI) logo
SWOG Cancer Research Network logo
Alliance for Clinical Trials in Oncology logo
NRG Oncology logo
ECOG-ACRIN Cancer Research Group logo
City of Hope logo
N
A
C
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems